XML 35 R32.htm IDEA: XBRL DOCUMENT v2.3.0.15
Equity-Based Compensation (Tables)
9 Months Ended
Oct. 01, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] 
Compensation Expense And Related Tax Benefit For Equity-Based Payments
     Three Months Ended      Nine Months Ended  
     October 1, 2011      October 2, 2010      October 1, 2011      October 2, 2010  

Cost of sales

   $ 218       $ 207       $ 755       $ 627   

Selling and marketing

     333         390         1,107         936   

Research and development

     343         302         1,037         963   

General and administrative

     2,204         1,600         7,149         4,312   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total compensation

   $ 3,098       $ 2,499       $ 10,048       $ 6,838   
  

 

 

    

 

 

    

 

 

    

 

 

 

Income tax benefit

   $ 1,069       $ 862       $ 3,467       $ 2,359   
  

 

 

    

 

 

    

 

 

    

 

 

 
Weighted-Average Assumptions Used For Grants Of Stock Options And SARs
October 1, 2011 October 1, 2011
     Nine Months Ended  
     October 1, 2011     October 2, 2010  

Expected dividend yield

     0     0

Forfeiture rate

     11.50     9.78

Volatility

     35.33     39.50

Risk free interest rate

     2.01     2.26

– Range of interest rates

     0.01% - 3.18     0.06% - 3.41

Expected weighted-average life

     5.42 years        5.36 years   

Fair value of options and SARs granted

   $ 5,495,000      $ 6,527,000   

Weighted-average grant date fair value of options and SARs granted

   $ 14.29      $ 10.65   
Summary Of Restricted Stock Award Activity
     Nine Months Ended October 1, 2011  

Restricted Stock Awards

   Shares     Weighted-Average
Grant Date Fair Value
 

Outstanding at beginning of year

     844,686      $ 25.46   

Granted

     214,324        41.32   

Vested

     (196,606     30.27   

Forfeited

     (15,780     28.75   
  

 

 

   

 

 

 

Outstanding at end of period

     846,624      $ 28.30   
  

 

 

   

 

 

 
Summary Of Award Granted Under Equity-Based Compensation Plans
     As of
October 1, 2011
 

Awards granted under Zebra's equity based compensation plans:

  

Unearned compensation costs related to awards granted

   $  20,619,000   

Period expected to be recognized over

     2.6 years   
Weighted-Average Assumptions Used For Employee Purchase Rights Granted Under Stock Purchase Plan
     Nine Months Ended  
     October 1, 2011     October 2, 2010  

Fair market value

   $ 35.86      $ 26.34   

Option price

   $ 34.07      $ 25.02   

Expected dividend yield

     0     0

Expected volatility

     32     27

Risk free interest rate

     0.09     0.13
Stock Appreciation Rights (SARs) [Member]
 
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] 
Summary Of SAR Activity
Weighted-Average Weighted-Average
     Nine Months Ended October 1, 2011  

SARs

   Shares     Weighted-Average
Exercise Price
 

Outstanding at beginning of year

     1,234,787      $ 23.82   

Granted

     384,649        41.20   

Exercised

     (81,793     22.02   

Forfeited

     (221,914     24.71   

Expired

     (273     19.56   
  

 

 

   

 

 

 

Outstanding at end of period

     1,315,456      $ 28.87   
  

 

 

   

 

 

 

Exercisable at end of period

     318,857      $ 23.26   
  

 

 

   

 

 

 

Intrinsic value of exercised SARs

   $ 1,539,000     
  

 

 

   
Summary Of Outstanding And Exercisable SAR
Stock Options [Member]
 
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] 
Summary Of Outstanding And Exercisable SAR
Summary Of Stock Option Activity
     Nine Months Ended October 1, 2011  

Options

   Shares     Weighted-Average
Exercise Price
 

Outstanding at beginning of year

     2,340,959      $ 37.36   

Granted

     0        0.00   

Exercised

     (370,612     25.88   

Forfeited

     (61,813     32.62   

Expired

     (57,683     40.07   
  

 

 

   

 

 

 

Outstanding at end of period

     1,850,851      $ 39.69   
  

 

 

   

 

 

 

Exercisable at end of period

     1,730,494      $ 40.08   
  

 

 

   

 

 

 

Intrinsic value of exercised options

   $ 5,079,000